Genzyme Corp Watch

from 10-K 8 pages Genzyme Europe B.V. Guarantee and Second Supplemental Indenture

from 8-K 44 pages Genzyme Corporation, First Supplemental Indenture Dated as of June 17, 2010 3.625% Senior Notes Due 2015 5.000% Senior Notes Due 2020 (First Supplemental Indenture to the Indenture Dated as of June 17, 2010) the Bank of New York Mellon Trust Company, N.A., as Trustee First Supplemental Indenture

from 8-K 64 pages Genzyme Corporation, as Issuer, and the Bank of New York Mellon Trust Company, N.A., as Trustee Indenture Dated as of June 17, 2010

from SC 13D/A 3 pages Genzyme Affirms Purchase Price for Bioenvision at $5.60 Per Outstanding Share

from SC 13D 17 pages Shareholder Support Agreement

from 8-K 4 pages Genzyme Corporation and U.S. Bank National Association as Trustee First Supplemental Indenture Dated as of May 28, 2004 to Indenture Dated as of December 9, 2003

from 8-A12G/A 41 pages Genzyme Corporation and American Stock Transfer & Trust Company, Rights Agent Fourth Amended and Restated Renewed Rights Agreement Dated as of May 28, 2004

from 8-K 20 pages This Security and the Common Stock Issuable Upon Conversion of This Security Have Not Been Registered Under the Securities Act of 1933, as Amended (The “Securities Act”), and May Not Be Offered, Sold, Pledged or Otherwise Transferred Except in Accordance With the Following Sentence. by Its Acquisition Hereof or of a Beneficial Interest Herein, the Acquirer: (1) Represents That It and Any Account for Which It Is Acting Is a “Qualified Institutional Buyer” (Within the Meaning of Rule 144a Under the Securities Act) and That It Exercises Sole Investment Discretion With Respect to Each Such Account, and (2) Agrees That It Will Not Directly or Indirectly Engage in Any Hedging Transactions Involving This Security or the Common Stock Issuable Upon Conversion of This Security Unless in Compliance With the Securities Act, And

from 8-K 93 pages Genzyme Corporation and U.S. Bank National Association as Trustee Indenture Dated as of December 9, 2003 Up to $690,000,000 Principal Amount 1.25% Convertible Senior Notes Due 2023

from 10-Q ~10 pages Indenture or similar

from 10-Q ~10 pages Indenture or similar

from 8-K ~20 pages Indenture or similar

from 8-K >50 pages Indenture or similar

from 8-K ~5 pages Indenture or similar

from 8-K ~20 pages Indenture or similar

from 8-A12G ~50 pages Indenture or similar

from S-3 ~50 pages Indenture or similar

from S-3 1 page Specimen Stock Certificate

from 8-A12G/A ~50 pages Amended and Restated Renewed Rights Agreement

from 8-K ~50 pages Renewed Rights Agreement